Rosetta Genomics Stock Price, News & Analysis (NASDAQ:ROSG)

$0.53 -0.10 (-15.87 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$0.63
Today's Range$0.50 - $0.63
52-Week Range$0.50 - $6.96
Volume921,224 shs
Average Volume145,420 shs
Market Capitalization$3.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31

About Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics logoRosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Receive ROSG News and Ratings via Email

Sign-up to receive the latest news and ratings for ROSG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ROSG
CUSIPN/A
Phone972-73-222-0700

Debt

Debt-to-Equity Ratio0.03%
Current Ratio2.10%
Quick Ratio2.10%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.23 million
Price / Sales0.31
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book0.22

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees86
Outstanding Shares5,400,000

Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."

How were Rosetta Genomics' earnings last quarter?

Rosetta Genomics Ltd. (NASDAQ:ROSG) released its earnings results on Thursday, May, 19th. The medical research company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The medical research company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.36 million. View Rosetta Genomics' Earnings History.

When will Rosetta Genomics make its next earnings announcement?

Rosetta Genomics is scheduled to release their next quarterly earnings announcement on Tuesday, December, 19th 2017. View Earnings Estimates for Rosetta Genomics.

Where is Rosetta Genomics' stock going? Where will Rosetta Genomics' stock price be in 2017?

1 brokerages have issued 1 year price targets for Rosetta Genomics' shares. Their forecasts range from $3.50 to $3.50. On average, they anticipate Rosetta Genomics' stock price to reach $3.50 in the next year. View Analyst Ratings for Rosetta Genomics.

Who are some of Rosetta Genomics' key competitors?

Who are Rosetta Genomics' key executives?

Rosetta Genomics' management team includes the folowing people:

  • Brian A. Markison, Chairman of the Board (Age 58)
  • Kenneth A Berlin, President, Chief Executive Officer (Age 51)
  • Ron Kalfus, Chief Financial Officer (Age 40)
  • Douglas Sites, Executive Vice President - Sales and Marketing
  • Dganit Bar Ph.D., Chief Scientific Officer (Age 46)
  • Eti Meiri Ph.D., Vice President - Research (Age 46)
  • Oded Biran, General Counsel (Age 36)
  • E. Robert Wassman M.D., Chief Medical Officer (Age 64)
  • Kevin Watson, Director, Reimbursement-Managed Care
  • Roy N. Davis, Director (Age 68)

How do I buy Rosetta Genomics stock?

Shares of Rosetta Genomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rosetta Genomics' stock price today?

One share of Rosetta Genomics stock can currently be purchased for approximately $0.53.

How big of a company is Rosetta Genomics?

Rosetta Genomics has a market capitalization of $3.53 million and generates $9.23 million in revenue each year. The medical research company earns $-16,230,000.00 in net income (profit) each year or ($11.04) on an earnings per share basis. Rosetta Genomics employs 86 workers across the globe.

How can I contact Rosetta Genomics?

Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected]


MarketBeat Community Rating for Rosetta Genomics (ROSG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rosetta Genomics (NASDAQ:ROSG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.16$2.16$2.61$2.71
Price Target Upside: 345.36% upside345.36% upside437.46% upside457.73% upside

Rosetta Genomics (NASDAQ:ROSG) Consensus Price Target History

Price Target History for Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ:ROSG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2017AegisReiterated RatingBuy$3.50N/AView Rating Details
9/7/2016S&P Equity ResearchLower Price Target$0.94 -> $0.82N/AView Rating Details
6/13/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
3/28/2016Barrington ResearchLower Price TargetOutperform$5.00 -> $3.50N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Rosetta Genomics (NASDAQ:ROSG) Earnings History and Estimates Chart

Earnings by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ ROSG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/19/2017        
9/26/2016Q216($0.17)($0.16)$2.89 million$2.41 millionViewListenView Earnings Details
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details
3/23/2016Q415($0.33)($0.14)$3.50 million$3.60 millionViewListenView Earnings Details
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Rosetta Genomics (NASDAQ:ROSG) Earnings Estimates

Current Year EPS Consensus Estimate: $-5.64 EPS
Next Year EPS Consensus Estimate: $-3.96 EPS

Dividends

Dividend History for Rosetta Genomics (NASDAQ:ROSG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rosetta Genomics (NASDAQ ROSG)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Rosetta Genomics (NASDAQ ROSG) News Headlines

Source:
DateHeadline
Genoptix to Acquire Rosetta Genomics for $10 Million in CashGenoptix to Acquire Rosetta Genomics for $10 Million in Cash
finance.yahoo.com - December 15 at 9:06 AM
Rosetta Genomics (ROSG) and Its Peers Head-To-Head ReviewRosetta Genomics (ROSG) and Its Peers Head-To-Head Review
www.americanbankingnews.com - December 9 at 3:14 AM
Financial Contrast: Rosetta Genomics (ROSG) and Its PeersFinancial Contrast: Rosetta Genomics (ROSG) and Its Peers
www.americanbankingnews.com - December 8 at 9:08 PM
Analyzing Rosetta Genomics (ROSG) and The CompetitionAnalyzing Rosetta Genomics (ROSG) and The Competition
www.americanbankingnews.com - December 8 at 3:30 PM
Rosetta Genomics (ROSG) and Its Peers Head to Head ComparisonRosetta Genomics (ROSG) and Its Peers Head to Head Comparison
www.americanbankingnews.com - December 6 at 1:28 AM
Rosetta Genomics (ROSG) and Its Rivals Financial ComparisonRosetta Genomics (ROSG) and Its Rivals Financial Comparison
www.americanbankingnews.com - December 4 at 7:42 PM
Head to Head Review: Rosetta Genomics (ROSG) versus The CompetitionHead to Head Review: Rosetta Genomics (ROSG) versus The Competition
www.americanbankingnews.com - December 2 at 11:30 PM
Rosetta Genomics (ROSG) Receives NASDAQ Notification on Minimum Bid PriceRosetta Genomics (ROSG) Receives NASDAQ Notification on Minimum Bid Price
www.streetinsider.com - December 2 at 11:09 AM
Analyzing Rosetta Genomics (ROSG) and Its RivalsAnalyzing Rosetta Genomics (ROSG) and Its Rivals
www.americanbankingnews.com - November 22 at 3:42 PM
Rosetta Genomics Provides Update on RosettaGX Reveal(TM)Rosetta Genomics Provides Update on RosettaGX Reveal(TM)
finance.yahoo.com - November 20 at 9:25 AM
Rosetta Genomics Expands Patent Protection for Thyroid microRNA Biomarkers with U.S. Patent AllowanceRosetta Genomics Expands Patent Protection for Thyroid microRNA Biomarkers with U.S. Patent Allowance
finance.yahoo.com - November 14 at 7:27 AM
Critical Survey: Rosetta Genomics (ROSG) versus Its RivalsCritical Survey: Rosetta Genomics (ROSG) versus Its Rivals
www.americanbankingnews.com - November 11 at 3:28 PM
Rosetta Genomics Receives NASDAQ NotificationRosetta Genomics Receives NASDAQ Notification
finance.yahoo.com - November 9 at 12:39 PM
Rosetta Genomics Ltd (ROSG): Time For A Financial Health CheckRosetta Genomics Ltd (ROSG): Time For A Financial Health Check
finance.yahoo.com - November 4 at 12:16 PM
Rosetta Genomics (ROSG) Says Favorable Data from Independent Study Comparing RosettaGX Reveal versus Afirma Presented at American Thyroid AssociationRosetta Genomics (ROSG) Says Favorable Data from Independent Study Comparing RosettaGX Reveal versus Afirma Presented at American Thyroid Association
www.streetinsider.com - October 24 at 9:24 AM
Favorable Data from Independent Study Comparing RosettaGX Reveal(TM) versus Afirma(R) to Accurately Classify Indeterminate Thyroid Nodules Were Presented at the 87th Annual Meeting of the American Thyroid AssociationFavorable Data from Independent Study Comparing RosettaGX Reveal(TM) versus Afirma(R) to Accurately Classify Indeterminate Thyroid Nodules Were Presented at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 24 at 9:24 AM
Rosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on WednesdayRosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 6:46 AM
The Worldwide Market for Lab-Developed Test Services and the Market for Instruments and Reagents Sold to LabsThe Worldwide Market for Lab-Developed Test Services and the Market for Instruments and Reagents Sold to Labs
www.bizjournals.com - October 18 at 1:29 AM
Rosetta Genomics Expands Patent Estate for Thyroid Cancer Detection microRNA Biomarkers with U.S. Patent AllowanceRosetta Genomics Expands Patent Estate for Thyroid Cancer Detection microRNA Biomarkers with U.S. Patent Allowance
finance.yahoo.com - October 17 at 3:23 PM
RosettaGX Reveal to be Highlighted in Poster Presentations at the 87th Annual Meeting of the American Thyroid AssociationRosettaGX Reveal to be Highlighted in Poster Presentations at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 17 at 6:53 AM
Rosetta Genomics and MediNcrease Health Plans Announce Provider Agreement Expanding Access to RosettaGX(TM) Reveal and Other Testing ServicesRosetta Genomics and MediNcrease Health Plans Announce Provider Agreement Expanding Access to RosettaGX(TM) Reveal and Other Testing Services
finance.yahoo.com - October 13 at 8:51 AM
Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial ResultsRosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results
finance.yahoo.com - October 11 at 7:14 AM
How Does Rosetta Genomics Ltd (ROSG) Affect Your Portfolio Returns?How Does Rosetta Genomics Ltd (ROSG) Affect Your Portfolio Returns?
finance.yahoo.com - October 6 at 7:29 AM
Rosetta Genomics Announces $2 Million Private PlacementRosetta Genomics Announces $2 Million Private Placement
finance.yahoo.com - October 3 at 11:51 AM
Rosetta Genomics (ROSG) Reports $2M Private Placement - StreetInsider.comRosetta Genomics (ROSG) Reports $2M Private Placement - StreetInsider.com
www.streetinsider.com - September 29 at 11:49 PM
Rosetta Genomics (ROSG) Reports $2M Private PlacementRosetta Genomics (ROSG) Reports $2M Private Placement
www.streetinsider.com - September 28 at 8:03 PM
Rosetta Genomics Ltd. (ROSG) Scheduled to Post Quarterly Earnings on WednesdayRosetta Genomics Ltd. (ROSG) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - September 27 at 1:04 AM
Rosetta Genomics (ROSG) Announces Sale of PersonalizeDx Business to Pragmin Prognosis for $2.875MRosetta Genomics (ROSG) Announces Sale of PersonalizeDx Business to Pragmin Prognosis for $2.875M
www.streetinsider.com - September 10 at 7:10 AM
Rosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin PrognosisRosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin Prognosis
finance.yahoo.com - September 9 at 8:03 AM
Rosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in JapanRosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in Japan
finance.yahoo.com - September 7 at 8:29 AM
Rosetta Genomics to Reduce Operating and Other ExpensesRosetta Genomics to Reduce Operating and Other Expenses
finance.yahoo.com - September 6 at 7:46 AM
Rosetta Genomics Ltd. (ROSG) Set to Announce Earnings on WednesdayRosetta Genomics Ltd. (ROSG) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - September 4 at 8:26 PM
Rosetta Genomics Ltd. (ROSG) to Release Earnings on MondayRosetta Genomics Ltd. (ROSG) to Release Earnings on Monday
www.americanbankingnews.com - August 24 at 8:08 PM
Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of ChoiceMajor Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice
finance.yahoo.com - August 22 at 6:21 AM
Rosetta Genomics Ltd. (NASDAQ:ROSG) to Release Earnings on WednesdayRosetta Genomics Ltd. (NASDAQ:ROSG) to Release Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:22 AM
Rosetta Genomics Announces Pricing of $2.73 Million FinancingRosetta Genomics Announces Pricing of $2.73 Million Financing
finance.yahoo.com - August 4 at 7:45 AM
Clinical Utility Survey Demonstrates the Potential of RosettaGX Reveal(TM) to Significantly Reduce Unnecessary Thyroid SurgeriesClinical Utility Survey Demonstrates the Potential of RosettaGX Reveal(TM) to Significantly Reduce Unnecessary Thyroid Surgeries
finance.yahoo.com - August 1 at 6:05 AM
RosettaGX Reveal(TM) to be Highlighted in Oral Presentation at the 3rd World Congress on Thyroid CancerRosettaGX Reveal(TM) to be Highlighted in Oral Presentation at the 3rd World Congress on Thyroid Cancer
finance.yahoo.com - July 27 at 7:00 AM
Rosetta Genomics Expands Patent Portfolio in Canada, United States, and ChinaRosetta Genomics Expands Patent Portfolio in Canada, United States, and China
finance.yahoo.com - July 6 at 8:34 AM
Full Year 2016 Rosetta Genomics Ltd Earnings Release - Before Market OpenFull Year 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open
biz.yahoo.com - March 30 at 7:51 PM
Rosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM AssayRosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay
us.rd.yahoo.com - March 20 at 5:40 PM
Rosetta Genomics (ROSG) Reports Patent for its Unique RosettaGX Reveal Assay - StreetInsider.comRosetta Genomics (ROSG) Reports Patent for its Unique RosettaGX Reveal Assay - StreetInsider.com
www.streetinsider.com - March 20 at 9:14 AM
Splits Calendar: Rosetta Genomics splits before market open today (1:12 ratio)Splits Calendar: Rosetta Genomics splits before market open today (1:12 ratio)
biz.yahoo.com - March 17 at 7:40 PM
Rosetta Genomics (ROSG) 1-for-12 Reverse Stock Split Effective Tomorrow - StreetInsider.comRosetta Genomics (ROSG) 1-for-12 Reverse Stock Split Effective Tomorrow - StreetInsider.com
www.streetinsider.com - March 17 at 1:29 AM
12:02 pm Rosetta Genomics announces 1:12 reverse stock split; will begin trading on a split-adjusted basis tomorrow at the open12:02 pm Rosetta Genomics announces 1:12 reverse stock split; will begin trading on a split-adjusted basis tomorrow at the open
us.rd.yahoo.com - March 16 at 8:27 PM
Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures - Business Wire (press release)Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures - Business Wire (press release)
www.businesswire.com - February 24 at 8:00 AM
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx Reveal TM microRNAsRosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx Reveal TM microRNAs
www.businesswire.com - February 6 at 8:43 AM
Aegis Restates Buy Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG)Aegis Restates 'Buy' Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG)
au.finance.yahoo.com - January 11 at 9:49 PM
BRIEF-Rosetta Genomics files for resale of up to 15.5 mln of cos ordinary shares by selling stockholdersBRIEF-Rosetta Genomics files for resale of up to 15.5 mln of co's ordinary shares by selling stockholders
www.reuters.com - December 8 at 8:01 PM
Q3 2016 Rosetta Genomics Ltd Earnings Release - After Market CloseQ3 2016 Rosetta Genomics Ltd Earnings Release - After Market Close
biz.yahoo.com - November 30 at 12:42 PM

SEC Filings

Rosetta Genomics (NASDAQ:ROSG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rosetta Genomics (NASDAQ:ROSG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rosetta Genomics (NASDAQ ROSG) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.